Calycosin (Astragalus Isoflavone · Phytoestrogenic · Immunomodulatory)

Compound	Calycosin (3′-Hydroxyformononetin; 7,3′-Dihydroxy-4′-methoxyisoflavone)
Chemical class	Polyphenol — Isoflavone (3-hydroxylated formononetin; primary isoflavone of Astragalus membranaceus)
CAS	20575-57-9
Primary source	Astragalus membranaceus (Huang Qi root — highest concentration), Astragalus mongholicus, Trifolium spp.
Key applications	Phytoestrogenic; immunomodulatory; cardiovascular; neuroprotective; antifibrotic
Claim strength	Moderate
Typical form	Astragalus Extract Powder; Polysaccharides 70% Huang Qi Extract (calycosin co-delivered as primary isoflavone); Cycloastragenol preparations
Buy from Herbuno	Astragalus Extract Powder (Astragalus gummifer) → Polysaccharides 70% Powder (Huang Qi Extract) | Standardized Astragalus membranaceus →

Name origin: Calycosin is named after Astragalus calycinus — one of the Astragalus species from which it was characterised — and represents the primary isoflavone of the Astragalus genus. Structurally, it is 3′-hydroxyformononetin — formononetin with an additional hydroxyl at the 3′ position of the B-ring, giving calycosin a catechol-adjacent B-ring substitution pattern that enhances antioxidant and enzyme interaction capacity relative to formononetin. Traditional use: Astragalus membranaceus (Huang Qi) is one of the most important tonic herbs in TCM — classified as a superior herb in the Shen Nong Ben Cao Jing and prescribed for Qi deficiency, immune weakness, spontaneous sweating, and cardiovascular conditions. Huang Qi is a core constituent of Bu Zhong Yi Qi Tang (Tonify the Middle and Augment the Qi decoction) and countless modern TCM immune-support formulas. Calycosin was identified as the primary isoflavone of Huang Qi alongside astragalosides (saponins) and astragalus polysaccharides — contributing the phytoestrogenic and antioxidant dimensions to Huang Qi's multi-mechanistic activity profile. Research trajectory: Calycosin has been studied for phytoestrogenic activity (ERβ agonism), cardiovascular protection, hepatoprotection, and most extensively for antifibrotic effects in liver and renal fibrosis models. Its ERβ selectivity is relevant to menopausal and bone applications, while its PI3K/Akt cardioprotective mechanism parallels formononetin but with greater potency attributed to the 3′-hydroxyl. Commercial source: Calycosin is available from Herbuno via Astragalus Extract Powder and Polysaccharides 70% Powder (Huang Qi Extract), both of which co-deliver calycosin as the primary Astragalus isoflavone alongside the immunomodulatory polysaccharide and triterpene saponin fractions.

---

Evidence for Calycosin Applications

Phytoestrogenic activity: Calycosin binds ERβ with greater affinity than formononetin due to its 3′-hydroxyl — providing ERβ-selective phytoestrogenic activity in breast cell models (ER-positive cell proliferation modulation), bone cell models (osteoblast differentiation promotion), and cardiovascular endothelial models (eNOS activation). In ovariectomised rodent models, calycosin attenuates bone loss and improves lipid profiles, with potency intermediate between genistein and formononetin. Claim strength: Moderate.

Immunomodulatory: Calycosin modulates dendritic cell maturation, NK cell activity, and Th1/Th2 balance in immune cell models — consistent with Astragalus's overall immunomodulatory profile. Its contribution to Astragalus preparations' clinical immune effects (improved leukocyte counts, reduced infection frequency in Chinese clinical studies) is proportional to its isoflavone fraction within the multi-component Huang Qi matrix. Claim strength: Moderate (extract); Emerging (isolated).

Cardiovascular protection: Calycosin activates PI3K/Akt/eNOS signalling in endothelial cells, increases NO production, and reduces ROS-induced endothelial apoptosis. In myocardial ischaemia-reperfusion rodent models, calycosin at 20–80 mg/kg reduces infarct size and preserves cardiac function. Vascular smooth muscle relaxation via Ca²⁺ channel modulation contributes to antihypertensive potential. Claim strength: Moderate (preclinical).

Antifibrotic: Calycosin inhibits TGF-β1/Smad signalling in hepatic stellate cells and renal tubular epithelial cells — the primary fibrogenic pathway. In CCl₄-induced liver fibrosis and diabetic nephropathy rodent models, calycosin reduces collagen deposition and fibrosis markers comparably to reference antifibrotic agents in some studies. Claim strength: Moderate (preclinical).

---

Dosage & Formulator Specification

No isolated calycosin human dosing data exist. In the context of Astragalus supplementation (500–3000 mg/day dried root equivalent, or 200–600 mg standardised extract), calycosin represents approximately 0.05–0.3% of total Astragalus extract weight — delivering 0.1–2 mg calycosin per serving depending on extract concentration. This is substantially below the concentrations used in preclinical efficacy studies (10–100 μg/mL in cell models, 10–80 mg/kg in animal models).

For calycosin-focused formulations, concentrated calycosin isolate (≥95% HPLC) from Astragalus root fractionation is available from specialty TCM phytochemistry suppliers. For Astragalus preparations where the full multi-component matrix (polysaccharides + saponins + isoflavones) is clinically relevant, Polysaccharides 70% Huang Qi Extract from Herbuno is the appropriate commercial specification — confirming polysaccharide content while co-delivering the calycosin isoflavone fraction.

Calycosin's bioavailability follows standard isoflavone pharmacokinetics — gut deglycosylation of the primary dietary conjugate (calycosin-7-glucoside) releasing aglycone for absorption. Plasma half-life is approximately 2–4 hours. ERβ activity requires 0.1–1 μM plasma concentrations — achievable from standard Astragalus supplementation only intermittently, suggesting calycosin's contribution to Astragalus's phytoestrogenic effects is modest at typical supplement doses.

Safety considerations: Astragalus is one of the most extensively used TCM herbs with an excellent safety record over millennia. Calycosin's phytoestrogenic activity should be noted in hormone-sensitive condition contexts. The 3′-hydroxyl group may enhance COMT-mediated methylation, potentially faster clearance than formononetin — limiting but also reducing duration of phytoestrogenic exposure.

---

Frequently Asked Questions — Calycosin

What distinguishes calycosin from formononetin pharmacologically?
Calycosin is formononetin with an additional 3′-hydroxyl on the B-ring. This single addition increases ERβ binding affinity, enhances radical scavenging capacity (catechol-like B-ring pattern), and alters cytochrome P450 metabolism (more rapid COMT-mediated methylation). Calycosin's antifibrotic and cardiovascular preclinical evidence is generally stronger than formononetin's in head-to-head comparisons, though both are minor isoflavones in their respective botanical sources.

Is calycosin the primary bioactive in Astragalus or secondary to the polysaccharides?
Astragalus membranaceus is a multi-component botanical where three distinct fractions contribute to its clinical activity: polysaccharides (primarily immunomodulatory), saponins/astragalosides (anti-ageing, telomerase activation via cycloastragenol), and isoflavones (calycosin, formononetin — phytoestrogenic, cardiovascular, antifibrotic). No single fraction is the primary bioactive; rather, Huang Qi's therapeutic breadth reflects the combined and synergistic activity of all three. For anti-ageing and telomere applications, cycloastragenol/astragalosides are primary; for immune modulation, polysaccharides are primary; for cardiovascular and phytoestrogenic effects, calycosin and formononetin contribute.

Can Astragalus extract be relied upon for calycosin delivery in supplement formulations?
Not for high-dose calycosin targeting — at 0.05–0.3% calycosin content in standard Astragalus extracts, doses of 200–600 mg extract deliver 0.1–2 mg calycosin, far below pharmacologically active concentrations in preclinical studies. Astragalus extract is appropriate when the full Huang Qi multi-component matrix is therapeutically intended. For calycosin-specific applications (phytoestrogenic, antifibrotic), concentrated calycosin isolate from specialty suppliers is necessary.

What is the relationship between calycosin and the traditional Huang Qi clinical evidence?
The extensive TCM clinical use and modern Chinese clinical studies for Astragalus (Huang Qi) preparations for immune support, cardiac conditions, and chronic disease management were conducted using whole root preparations — not calycosin isolate. Calycosin's role within these preparations is one of multiple contributing mechanisms. The traditional evidence for Huang Qi cannot be directly attributed to calycosin alone; it reflects the integrated multi-component botanical activity. This distinction is important for regulated structure-function claims.

Related compounds: Formononetin, Biochanin A, Puerarin, Genistein

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery